Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...

Incyte is abandoning its ALK2 blocker zilurgisertib, which it was trialing for myelofibrosis-associated anemia, while iTeos ...

Ocaliva recently failed to secure the FDA’s traditional approval for primary biliary cholangitis due to safety concerns.

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

The EPIC Act has been proposed with bipartisan and industry support to give small molecule drugs the same protection against ...

BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech ...

The company had said in October said that it was looking to license out its ex vivo editor renizgamglogene autogedtemcel to ...

By speeding lifesaving drugs’ way to market and focusing on the underlying causes of disease, the pathway has helped save ...

Around 25 companies have gone public this year, most of them in the early months. Most have tumbled from their original offer ...

The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to support it. Meanwhile, the makers of these drugs have been reporting double-digit ...

The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of ...

Ending the diagnostic journey for patients, particularly those with rare diseases, improves patients' quality of life while ...